Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Drugs of the Future - Bispecific Antibodies: An investigaion of future development needs
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Biology Education Centre.
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Biology Education Centre.
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Biology Education Centre.
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Biology Education Centre.
Show others and affiliations
2019 (English)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesis
Abstract [en]

This report reviews the field of bispecific antibodies, artificially engineered antibodies thathave the ability to bind two or more different antigen simultaneously. Historical as well asrecently developed techniques are demonstrated, together with formats in preclinical andclinical development. We studied the field with the future needs of the developers in mind,when it comes to the processes and tools that can be offered by GE Healthcare BiosciencesAB.

The development of bispecific antibodies gave rise to new challenges and product-relatedimpurities, which are handled by various methods. We argue for, based on the formats inclinical and preclinical development, that the methods already used to purify monospecificantibodies remain the most successful methods for the purification of bispecific antibodies.This, together with the design strategies that resolve the initial bottle-necks, ensures that theneeds of the developers are met to the same extent as for monoclonal antibodies. The methodsand formats demonstrated here do not represent all that are available or under trial.

Place, publisher, year, edition, pages
2019. , p. 70
Keywords [en]
bispecific, antibodies, antibody, production, preclinical, clinical, development, knob-into-hole, Duetmab, crossmab, beat, orthogonal, fab
National Category
Pharmaceutical Biotechnology
Identifiers
URN: urn:nbn:se:uu:diva-384685OAI: oai:DiVA.org:uu-384685DiVA, id: diva2:1321277
Educational program
Molecular Biotechnology Engineering Programme
Supervisors
Examiners
Available from: 2019-06-07 Created: 2019-06-07 Last updated: 2019-06-07Bibliographically approved

Open Access in DiVA

Drugs_of_the_future_Bispecific_antibodies(2647 kB)169 downloads
File information
File name FULLTEXT01.pdfFile size 2647 kBChecksum SHA-512
9d2d0ba20e9bd4176c567dc288c1c7682382dcecf9077c712cd27b2d5e9e220c4d62bd5f2155940f926269354443584db8dd62b327a085f1b9f6cf7c3723cf3f
Type fulltextMimetype application/pdf

By organisation
Biology Education Centre
Pharmaceutical Biotechnology

Search outside of DiVA

GoogleGoogle Scholar
Total: 169 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 208 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf